In a move to enhance its diabetes portfolio in India, Indianapolis, Indiana-based Eli Lilly launched a once-a-week diabetes treatment drug under the brand name Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, a hormone that helps normalize blood sugar levels in those with Type 2 diabetes, reports BusinessLine.
Priced at $37.15, the drug comes as a single-dose pen that does not require mixing or measuring and can be administered at any time of the day, independent of meals, company officials said.
Managing Director of Eli Lilly India, Edgard Olaizola, told Press Trust of India, “We are pleased to be introducing Trulicity in India. We have been committed to diabetes for more than 90 years. We are bringing a new medication to India with a proven efficacy.”
India has more than 60 million people diagnosed with some form of diabetes, with Type 2 the most prevalent. The International Diabetes Foundation estimates India will have 100 million diabetes patients by 2030, with 90% Type 2.
